Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 8.01 (Other Events). Total debt issuance $8B across 7 tranches, ranging from floating rate to 40-year notes (2066), closing March 4, 2026.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Total debt issuance $8B across 7 tranches, ranging from floating rate to 40-year notes (2066), closing March 4, 2026
- Net proceeds ~$7.95B; $2B earmarked to repay 364-day term loan maturing May 2026, remainder for general corporate/debt purposes
- Fixed coupon rates: 3.775% (2028), 4.125% (2031), 4.400% (2033), 4.750% (2036), 5.550% (2056), 5.650% (2066); signals AbbVie locking in long-term capital at current rates
- Largest tranches: $1.5B each in 2028 and 2036 Notes, suggesting preference for near- and medium-term maturities
- Significant leverage signal: $8B raise well exceeds the $2B term loan obligation, implying substantial additional debt refinancing or strategic spend ahead
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.